Introduction: Type-2 diabetes is considered as second highly non-communicable disorder, prior to hypertension, in terms of public health importance. It is a metabolic disorder resulting from the body’s inability to produce sufficient amount of insulin or properly utilise the same. Terminalia catappa is a large tropical tree from the Combretaceae family whose leaves are widely used as a folk medicine in Southeast Asia for the treatment of dermatitis and hepatitis. Aims and Objectives: The current study aimed to Characterise Terminalia catappa leaf extract by Fourier transform Infrared (FTIR) procedure and also to examine the In-Vitro anti-diabetic Potential of Terminalia catappa leaves via the inhibition of α-Amylase and α-Glucosidase enzymes. Methodology: The extracts were obtained by successive solvent extraction of leaf using Petroleum ether, chloroform and 70% ethanol, following which the extracts were subjected to preliminary phytochemical screening showing the presence of various phytoconstituents. Anti-diabetic potential of the extract was determined at concentrations 20, 40, 60, 80 and 100 μg/mL for ana lysing α-Amylase and α-Glucosidase along with the standard Acarbose. Results: The results indicated the presence of beneficial phytoconstituents like flavonoids, Saponins, Alkaloids and Cardiac glycosides. The ethanolic extract exhibited inhibition of α-Amylase and α-Glucosidase enzymes. The results of the α-amylase and α-glucosidase inhibition assay demonstrated a clear concentration-dependent antidiabetic activity for both the standard drug and the test compound. Fourier-transform infrared spectroscopy was used to detect the functional groups of phytochemicals present in the plant extract. Conclusion: The study concludes that the ethanolic extract of leaves of Terminalia catappa possess the promising antidiabetic activity through α-Amylase and α-Glucosidase inhibition.